RT Journal Article
SR Electronic
T1 Epidemiological differences in the impact of COVID-19 vaccination in the United States and China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249380
DO 10.1101/2021.01.07.21249380
A1 Makhoul, Monia
A1 Chemaitelly, Hiam
A1 Ayoub, Houssein H.
A1 Seedat, Shaheen
A1 Abu-Raddad, Laith J.
YR 2021
UL http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249380.abstract
AB Background The objective of this study was to forecast the impact of COVID-19 vaccination in the United States (US) and China, two countries at different epidemic phases.Methods A mathematical model describing SARS-CoV-2 transmission and disease progression was used to investigate vaccine impact. Impact was assessed both for a vaccine that prevents infection (VES = 95%) and a vaccine that prevents only disease (VEP = 95%).Results For VES = 95% and gradual easing of restrictions, vaccination in the US reduced the peak incidence of infection, disease, and death by >55% and cumulative incidence by >32%, and in China by >77% and >65%, respectively. Nearly three vaccinations were needed to avert one infection in the US, but only one was needed in China. For VEP = 95%, benefits of vaccination were half those for VES = 95%. In both countries, the impact of vaccination was substantially enhanced with rapid scale-up, vaccine coverage >50%, and slower or no easing of restrictions, particularly in the US.Conclusions COVID-19 vaccination can flatten, delay, and/or prevent future epidemic waves. However, vaccine impact is destined to be heterogeneous across countries because of an underlying “epidemiologic inequity” that reduces benefits for countries already at high incidence, such as the US. Despite 95% efficacy, actual vaccine impact could be meager in such countries, if vaccine scale-up is slow, acceptance of the vaccine is poor, or restrictions are eased prematurely.One Sentence Summary Vaccine impact will be heterogeneous across countries disadvantaging countries at high incidence. This heterogeneity can be alleviated with rapid vaccination scale-up and limited easing of restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe developed mathematical models were made possible by NPRP grant number 9-040-3-008 (Principal investigator: LJA) and NPRP grant number 12S-0216-190094 (Principal investigator: LJA) from the Qatar National Research Fund (a member of Qatar Foundation; https://www.qnrf.org). The statements made herein are solely the responsibility of the authors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript and its supplementary materials. Code programmed in MATLAB can be obtained from the authors.